Kartos Therapeutics

Kartos Therapeutics, based in Redwood City, the United States, is a biotechnology company. Kartos Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapeutics for patients with cancer. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing KRT-232 and Ruxolitinib in myeloproliferative neoplasms, endometrial cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and hodgkin lymphoma. The largest, NCT05797831 (Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer), plans to enrol 268 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.